Davita Inc (NYSE:DVA) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 5,500,000 shares, a decline of 5.2% from the April 30th total of 5,800,000 shares. Based on an average daily volume of 1,690,000 shares, the days-to-cover ratio is currently 3.3 days. Approximately 4.6% of the company’s stock are short sold.
In other Davita news, Director Paul J. Diaz sold 5,763 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $82.22, for a total transaction of $473,833.86. Following the completion of the sale, the director now owns 15,749 shares in the company, valued at approximately $1,294,882.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John M. Nehra sold 7,694 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $80.74, for a total transaction of $621,213.56. The disclosure for this sale can be found here. Insiders have sold a total of 39,472 shares of company stock valued at $3,195,739 in the last 90 days. 1.10% of the stock is currently owned by company insiders.
Several large investors have recently modified their holdings of the stock. Norges Bank purchased a new position in shares of Davita in the 4th quarter worth about $262,843,000. Bank of New York Mellon Corp lifted its holdings in Davita by 25.4% during the first quarter. Bank of New York Mellon Corp now owns 2,752,320 shares of the company’s stock valued at $209,343,000 after purchasing an additional 556,781 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Davita by 9.6% during the fourth quarter. Geode Capital Management LLC now owns 1,697,618 shares of the company’s stock valued at $127,148,000 after purchasing an additional 148,112 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in Davita by 609.0% during the first quarter. Robeco Institutional Asset Management B.V. now owns 1,391,608 shares of the company’s stock valued at $105,847,000 after purchasing an additional 1,195,328 shares during the last quarter. Finally, Boston Partners lifted its holdings in Davita by 4.2% during the fourth quarter. Boston Partners now owns 863,825 shares of the company’s stock valued at $64,813,000 after purchasing an additional 34,801 shares during the last quarter. 95.66% of the stock is currently owned by institutional investors.
Shares of NYSE:DVA opened at $76.81 on Friday. The company’s 50-day moving average is $76.35 and its 200 day moving average is $75.89. The company has a debt-to-equity ratio of 5.24, a quick ratio of 1.77 and a current ratio of 1.81. The company has a market capitalization of $9.59 billion, a P/E ratio of 12.08, a price-to-earnings-growth ratio of 1.41 and a beta of 1.22. Davita has a fifty-two week low of $43.40 and a fifty-two week high of $90.15.
Davita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.47 by $0.36. The company had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.84 billion. Davita had a net margin of 7.85% and a return on equity of 32.45%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.91 EPS. As a group, research analysts predict that Davita will post 6.13 earnings per share for the current year.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.